90. J Exp Clin Cancer Res. 2018 Mar 27;37(1):72. doi: 10.1186/s13046-018-0741-3.The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.Cretella D(1), Ravelli A(1), Fumarola C(2), La Monica S(1), Digiacomo G(1),Cavazzoni A(1), Alfieri R(1), Biondi A(1), Generali D(3)(4), Bonelli M(1),Petronini PG(1).Author information: (1)Department of Medicine and Surgery, University of Parma, Parma, Italy.(2)Department of Medicine and Surgery, University of Parma, Parma, Italy.claudia.fumarola@unipr.it.(3)Department of Medical, Surgery and Health Sciences, University of Trieste,Trieste, Italy.(4)U.O. Multidisciplinare di Patologia Mammaria, U.S Terapia Molecolare eFarmacogenomica, ASST Cremona, Cremona, Italy.DOI: 10.1186/s13046-018-0741-3 PMCID: PMC5872523PMID: 29587820 